SPOKANE, Wash., Oct. 1, 2025 /PRNewswire/ -- Gestalt, a leader in digital pathology and AI-driven laboratory solutions, is proud to announce...
VISTA, Calif., Oct. 1, 2025 /PRNewswire/ -- In a groundbreaking showcase of innovation designed to accelerate the digital transformation of...
Favorable End-of-Phase 2 meeting with U.S. FDA for FAPI-74 for GI cancers Primary and secondary endpoints met Alignment with FDA...
Copay Assistance From The Assistance Fund Now Available for Eligible People Living With B-Cell Lymphoma ORLANDO, FL / ACCESS Newswire...
MESA, ARIZONA / ACCESS Newswire / October 1, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), an emerging developer of...
Secure, scalable, multi-cloud platform using federated learning aims to accelerate cancer discoveries and treatments SEATTLE, WASHINGTON / ACCESS Newswire /...
The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement1 with new...
Strategic Expansion with Leading Franchise Network Underscores Revenue Potential and Market Leadership for SteraMist iHP TechnologyFREDERICK, Md., Oct. 01, 2025...
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of...
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica...
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc....
PARAMUS, N.J., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with...
MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical...
Phase 1 study to progress to the next dose level of 75mCi in patients with HER2+ advanced solid tumors, instead...
Also, six new projects from previous NSF/CASIS joint solicitations were selected to advance tissue engineering and transport phenomena research through...
JERSEY CITY, N.J., Sept. 30, 2025 /PRNewswire/ -- OMI Pulse recently received recognition as a recognized quality solution for pathway...
JERSEY CITY, N.J., Sept. 30, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services,...
UPPSALA, Sweden, Sept. 30, 2025 /PRNewswire/ -- Navinci today announced the launch of the Naveni® Plex Omni Service, a new offering...
The collaboration combines multimodal database technology, advanced AI agents, and large-scale datasets to accelerate drug discovery. SAN FRANCISCO, Sept. 30,...
In this free webinar, understand why traditional 3+3 dose escalation designs are increasingly unsuitable for modern oncology drug development. Attendees...